{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=111", "query": { "condition": "Advanced Malignancy", "page": 111 }, "page_size": 10 }, "pagination": { "page": 111, "page_size": 10, "total_count": 9820, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=112&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=110&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T23:24:50.210Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02216409", "title": "Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Hu5F9-G4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2014-08", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2019-02-05", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 6, "location_summary": "Stanford, California • Chicago, Illinois • Grand Rapids, Michigan + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02216409" }, { "nct_id": "NCT07161414", "title": "A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "IV Rilvegostomig", "type": "DRUG" }, { "name": "Recombinant Human Hyaluronidase (rHu)", "type": "DRUG" }, { "name": "SC Rilvegostomig", "type": "DRUG" }, { "name": "SC rilvegostomig + rHu", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-11-25", "completion_date": "2029-07-24", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 3, "location_summary": "Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07161414" }, { "nct_id": "NCT00254904", "title": "Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "PF-3512676", "type": "DRUG" }, { "name": "Gemcitabine + Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 839, "start_date": "2005-11", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2015-03-30", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Bakersfield, California • Saint Joseph, Michigan + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Saint Joseph", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00254904" }, { "nct_id": "NCT01129349", "title": "Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Oprozomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2010-04", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129349" }, { "nct_id": "NCT00575393", "title": "Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "gold sodium thiomalate", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "fluorine F 18 fluorothymidine", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 17, "start_date": "2007-01-25", "completion_date": "2012-02-14", "has_results": false, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00575393" }, { "nct_id": "NCT03951116", "title": "Study of FCN-437c in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FCN-437", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fochon Pharmaceuticals, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-06-25", "completion_date": "2021-12-08", "has_results": false, "last_update_posted_date": "2022-03-16", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 3, "location_summary": "Duarte, California • Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03951116" }, { "nct_id": "NCT03017833", "title": "Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Refractory Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2018-03-12", "completion_date": "2022-12-21", "has_results": false, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03017833" }, { "nct_id": "NCT04005144", "title": "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Gene Rearrangement", "Lung Non-Small Cell Carcinoma", "Progressive Disease", "ROS1 Gene Rearrangement", "Stage IIIB Lung Cancer", "Stage IIIC Lung Cancer", "Stage IV Lung Cancer", "Stage IVA Lung Cancer", "Stage IVB Lung Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Brigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-02-25", "completion_date": "2022-10-01", "has_results": false, "last_update_posted_date": "2022-10-17", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005144" }, { "nct_id": "NCT00002519", "title": "Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "1997-01", "completion_date": "2000-01", "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 3, "location_summary": "Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002519" }, { "nct_id": "NCT01502800", "title": "Clinical Trial of ARQ 761 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ARQ 761", "type": "DRUG" }, { "name": "ARQ 761 Weekly Administration", "type": "DRUG" }, { "name": "Bi-Weekly Administration of ARQ 761", "type": "DRUG" }, { "name": "Two Consecutive Weeks Administration of ARQ 761 with one week of rest", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2011-12-29", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-11-12T23:24:50.210Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01502800" } ] }